Physician profile
Christopher M King
NPI 1043474844
$4,857.23
in general payments reported to CMS, 2019-2025
42 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $90.24 · 2021: $653 · 2022: $653 · 2023: $568 · 2024: $1,304 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197 · Debt Forgiveness: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.02 |
| Debt Forgiveness | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,921.62 | 2021-2025 | |
| Pfizer INC. | $349.88 | 2023-2025 | |
| Mdd US Operations, LLC | $275.96 | 2024 | Gocovri |
| Ucb, INC. | $272.35 | 2021-2025 | Rystiggo, Nayzilam, Briviact |
| Biogen, INC. | $169.38 | 2022-2024 | Vumerity, Tysabri |
| Eisai INC. | $153.26 | 2025 | |
| Amneal Pharmaceuticals LLC | $125.00 | 2019 | |
| Livanova USA, INC. | $120.23 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $115.70 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $107.79 | 2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $94.45 | 2024-2025 | Ultomiris |
| Tg Therapeutics, INC. | $78.66 | 2024 | |
| Argenx US, INC. | $72.93 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $72.83 | 2024-2025 | Vyepti |
| Allergan, INC. | $70.54 | 2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.